Primecap Management Co. CA decreased its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 2.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,455,819 shares of the life sciences company's stock after selling 60,540 shares during the period. Primecap Management Co. CA owned about 1.55% of Illumina worth $328,171,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also modified their holdings of the company. Versant Capital Management Inc increased its holdings in Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after purchasing an additional 146 shares during the period. Golden State Wealth Management LLC purchased a new stake in shares of Illumina during the fourth quarter worth approximately $32,000. Assetmark Inc. increased its stake in shares of Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after buying an additional 296 shares during the period. Bank Julius Baer & Co. Ltd Zurich purchased a new position in Illumina in the fourth quarter worth approximately $45,000. Finally, TD Private Client Wealth LLC grew its holdings in Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company's stock worth $50,000 after acquiring an additional 141 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.
Illumina Stock Performance
NASDAQ:ILMN traded up $2.87 during mid-day trading on Friday, reaching $87.66. The stock had a trading volume of 3,822,397 shares, compared to its average volume of 2,094,739. Illumina, Inc. has a twelve month low of $80.18 and a twelve month high of $156.66. The business has a 50 day simple moving average of $109.19 and a 200 day simple moving average of $128.58. The firm has a market capitalization of $13.89 billion, a price-to-earnings ratio of -11.41, a PEG ratio of 1.60 and a beta of 1.17. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77.
Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several research firms have recently issued reports on ILMN. HSBC cut shares of Illumina from a "buy" rating to a "hold" rating and set a $100.00 price objective for the company. in a research report on Friday, February 28th. Barclays reaffirmed an "underweight" rating on shares of Illumina in a report on Tuesday, March 11th. Robert W. Baird cut their target price on Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a research report on Wednesday, March 5th. Canaccord Genuity Group decreased their target price on Illumina from $135.00 to $115.00 and set a "hold" rating for the company in a research note on Tuesday, March 11th. Finally, Citigroup cut their price objective on shares of Illumina from $130.00 to $90.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Illumina presently has an average rating of "Moderate Buy" and an average price target of $140.90.
View Our Latest Stock Analysis on Illumina
About Illumina
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Featured Articles
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
